Risk stratification for febrile neutropenia in patients with testicular germ cell tumors

Angelika Terbuch1,2, Florian Posch1,2, Richard Partl3, Brigitte Zurl3, Thomas Bauernhofer1,4, Martin Pichler1,5, Joanna Szkandera1, Georg C. Hutterer5, Karl Pummer6, Karin S. Kapp3, Herbert Stöger1, Armin Gerger1,2,4 & Michael Stotz1,2

1Division of Oncology, Department of Internal Medicine, Comprehensive Cancer Center Graz, Medical University of Graz, Graz, Austria
2Research Unit Genetic Epidemiology and Pharmacogenetics, Medical University of Graz, Graz, Austria
3Department of Therapeutic Radiology and Oncology, Comprehensive Cancer Center Graz, Medical University of Graz, Graz, Austria
4Center for Biomarker Research in Medicine (CBmed), Graz, Austria
5Department of Experimental Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, Texas
6Department of Urology, Medical University of Graz, Graz, Austria

Keywords
Testicular cancer, febrile neutropenia, risk factors, radiotherapy, chemotherapy

Abstract
The aim of this study was to detect risk factors for febrile neutropenia (FN) in patients with testicular germ cell tumors (TGCT). In this retrospective cohort study at the Medical University of Graz, we included 413 consecutive TGCT patients who received adjuvant or curative treatment with cisplatin-based chemotherapy. FN occurred in 70 (16.9%) of 413 patients. In univariable logistic regression, higher age (odds ratio (OR) per 5 years = 1.17, 95% CI: 1.02–1.35, P = 0.022), reduced performance status (PS) (OR = 2.73, 1.47–5.06, P = 0.001), seminomatous histology (OR = 2.19, 1.26–3.78, P = 0.005), poor IGCCCG risk class (OR = 4.20, 1.71–10.33, P = 0.002), and prior radiotherapy (pRTX) (OR = 8.98, 2.09–38.61, P = 0.003) were associated with a higher risk of FN. In multivariable analysis adjusting for age and risk classification, only poor PS (OR = 2.06, 1.05–4.03, P = 0.035), seminomatous histology (OR = 2.08, 1.01–4.26, P = 0.047), and pRTX (OR = 7.31, 1.61–33.17, P = 0.010) prevailed. In the subgroup of seminoma patients (n = 104), only pRTX predicted for FN risk (OR = 5.60, 1.24–25.34, P = 0.025). Five of eight seminoma patients with pRTX developed FN (63%), as compared to 22 FN cases (23%) in the 96 seminoma patients without pRTX (P = 0.027). The eight seminoma patients who received pRTX had significantly lower pre-chemo white blood counts (4.7 vs. 6.5 G/L), neutrophil counts (3.2 vs. 4.3 G/L), and platelet counts (185 vs. 272 G/L) than patients without pRTX (all P < 0.0001). TGCT patients with a reduced performance status or who had been previously treated with radiotherapy have an increased risk for neutropenic fever during chemotherapy.

Introduction
Testicular germ cell tumors (TGCT) represent the most common solid malignancy among men aged 15–40 years and can be divided into two subgroups: seminomatous (SGCT) and nonseminomatous germ cell tumors (NSGCT) [1]. Long-term prognosis of testicular germ cell tumors (TGCT) is excellent. The 5-year survival rate of patients with TGCT in stage I approximates 99%. Treatment options for stage I seminoma are active surveillance, adjuvant treatment with one cycle of carboplatin or adjuvant radiotherapy [2, 3]. NSGCT patients with stage I disease can be managed with active surveillance or may be offered one adjuvant chemotherapy cycle with bleomycin, etoposide, and cisplatin (BEP) [4]. For metastatic cases, the International Germ Cell Cancer Collaborative Group (IGCCCG) has identified three prognostic groups: good, intermediate, and poor risk. With optimal management the 5-year survival rate approximates 91%, 79% and 48% in metastatic disease with good, intermediate and poor...
prognosis [5, 6]. Depending on the prognostic group three or four cycles of BEP represent the standard of care for relapsed or metastatic disease. In stage II A disease, also radiotherapy for seminoma and retroperitoneal lymph node dissection (RPLND) for nonseminoma are valid treatment options [1, 5].

However, treatment is associated with non-negligible complications and a negative impact on quality of life [7–11]. Therefore, optimizing the complication rate of TCGT treatment holds promise to further increase the already favorable prognosis of these patients.

Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy. FN rates during curative BEP chemotherapy are between 10 and 20%. Routine prophylactic use of granulocyte colony-stimulating factors (G-CSF) is not recommended [12]. A personalized FN risk stratification approach to the patient with TCGT in need of systemic chemotherapy may optimize the indication and thus risk-benefit ratio of prophylactic G-CSF support in this population. Thus, the aim of this study was to identify prognostic factors for FN in order to delineate subgroups with the highest risk of FN.

Materials and Methods

Subjects

All consecutive patients (n = 960) with histologically confirmed TGCT, presenting to the Division of Oncology at the Medical University of Graz between January 1994 and September 2013, were retrospectively reviewed. Patients were initially staged using computed tomographic (CT) scans of the abdomen, CT scan or X-ray of the chest, and postoperative tumor markers α-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH). Patients with disseminated disease were stratified according to the IGCCCG risk classification [13, 14].

Follow-up data were retrieved until January 2015. Follow-up investigations at our center were performed according to a local protocol and were adapted in 2007 and 2012 according to recent publications [15–17]. Because the primary endpoint of this study was the risk of febrile neutropenia in patients undergoing cisplatin-based chemotherapy, patients who were managed with active surveillance, adjuvant or curative radiotherapy, adjuvant carboplatin and did not experience relapse were excluded from further analysis (n = 547). A total of 413 patients who received adjuvant or curative cisplatin-based chemotherapy during the course of disease were selected for this study (Table 1). A total of 377 (91%) of 413 patients had not received any treatment (except orchiectomy) prior to cisplatin-based chemotherapy, eight (2%) patients had undergone adjuvant or curative radiotherapy to paraaortic/iliac lymph nodes prior to chemotherapy and one (0%) patient had received one cycle of adjuvant carboplatin. Because 27 patients received several cycles of cisplatin-based chemotherapy, all cycles were counted until an episode of FN occurred. In patients without any FN episode, all cycles of cisplatin-based chemotherapy were counted. Electronic and paper medical records of all 413 consecutive TGCT patients were retrospectively reviewed, and febrile neutropenia was documented in our in-house administrative system. FN was defined as an oral temperature of >38.3°C or two consecutive readings of >38.0°C for 2 h and an absolute neutrophil count (ANC) of <0.5 × 10⁹/L, or expected to fall below 0.5 × 10⁹/L [18].

The study was approved by the Institutional Review Board of the Medical University of Graz (No. 26-196 ex 13/1).

Statistical methods

All statistical analyses were performed using Stata (Version 14.0, Stata Corp., Houston, TX) and IBM SPSS Statistics (Release 23.0.0. 2015. Chicago (IL), USA: SPSS Inc., an IBM Company). Continuous variables were reported as medians [25th–75th percentile] and count data as absolute frequencies (%). Means between two or more groups were compared with t-tests, rank-sum tests, and Kruskal–Wallis tests, respectively. Spearman’s rank-based correlation coefficient was used for examining the correlation between radiotherapy parameters and blood counts. The association between FN and clinical covariables was quantified with uni- and multivariable logistic regression [19].

Results

Analysis at Baseline

Characterization of FN episodes

During a total number of 1.196 chemotherapy cycles [median: 3, (IQR: 2–3, range: 1–6)], we observed 70 episodes of febrile neutropenia (16.9%) (Table 1). In 55 (79%) of these 70 events, the episode occurred during the first cycle of treatment. In 10 (14%), two (3%), and three (4%) of patients, the episode occurred during the 2nd, 3rd and 4th cycle of treatment. The median time between CTX start and FN onset was 14 days (IQR: 12–15, range: 7–18). One (1%) FN episode was fatal, and 56 patients (80%) had to be hospitalized. The median time in hospital was 7 days (IQR: 6–8, range: 3–12), and the median number of days with an absolute neutrophil count below 0.5 G/L was 2 (IQR: 2–3, range: 1–7). Sixty (14.5%) of 413 patients received primary GCSF support. Twelve
Table 1. Baseline characteristics of the patient population – Distribution overall and by febrile neutropenia.

| Variable                          | n (% missing) | Overall (n = 413) | No febrile neutropenia during CTX (n = 343) | Febrile neutropenia during CTX (n = 70) | \(P^1\) |
|-----------------------------------|--------------|------------------|------------------------------------------|--------------------------------------|--------|
| Demographic characteristics       |              |                  |                                          |                                      |        |
| Age                               | 413 (0.0%)   | 34 [27–40]       | 33 [27–40]                               | 36 [28–42]                           | 0.052  |
| BMI                               | 274 (34%)    | 25 [22–27]       | 25 [22–27]                               | 24 [22–26]                           | 0.439  |
| Smoker or ex-smoker               | 298 (28%)    | 169 (57%)        | 146 (59%)                                | 23 (47%)                             | 0.131  |
| Karnofsky index < 100%            | 371 (10%)    | 61 (16%)         | 41 (13%)                                 | 20 (30%)                             | 0.001  |
| Clinicopathological variables     |              |                  |                                          |                                      |        |
| Seminomatous histology            | 408 (0%)\(^2\) | 104 (25%)       | 77 (23%)                                 | 27 (39%)                             | 0.004  |
| T Stage                           | 375 (9%)     | /                | /                                        | /                                    | 0.088  |
| pT1                               | /            | 164 (44%)        | 142 (45%)                                | 22 (36%)                             | /      |
| pT2                               | /            | 143 (38%)        | 121 (39%)                                | 22 (36.0%)                           | /      |
| pT3                               | /            | 68 (18%)         | 51 (16%)                                 | 17 (28%)                             | /      |
| pT4                               | 0 (0%)       | 0 (0.0%)         | 0 (0.0%)                                 | 0 (0.0%)                             |        |
| Adjuvant treatment\(^3\)          | 413 (0%)     | 141 (34%)        | 126 (37%)                                | 15 (21%)                             | 0.014  |
| IGCCCG                            | 272 (0%)     |                  |                                          |                                      |        |
| Good risk                         |              | 203 (75%)        | 167 (77%)                                | 36 (65%)                             | 0.112  |
| Intermediate risk                 |              | 36 (13%)         | 28 (13%)                                 | 8 (15%)                              |        |
| Poor risk                         |              | 33 (12%)         | 22 (10%)                                 | 11 (20%)                             |        |
| Synchronous metastasis            | 272 (0%)     | 232 (85%)        | 185 (85%)                                | 47 (85%)                             | 0.970  |
| Primary G-CSF support             | 345 (16%)    | 60 (17%)         | 48 (17%)                                 | 12 (19%)                             | 0.751  |
| Prior treatment\(^4\)             | 413 (0%)     |                  |                                          |                                      | 0.001  |
| No prior treatment                | 377 (91%)    | 318 (93%)        | 318 (93%)                                | 59 (84%)                             |        |
| Radiotherapy                      | 8 (2%)       | 3 (1%)           | 5 (7%)                                   |                                      |        |
| Adjuvant carboplatin              | 1 (0%)       | 1 (0%)           | 0 (0%)                                   |                                      |        |
| 2 cycles PEB                      | 2 (0%)       | 1 (0%)           | 1 (1%)                                   |                                      |        |
| 3 cycles PEB                      | 2 (0%)       | 1 (0%)           | 1 (1%)                                   |                                      |        |
| 4 cycle PEB                       | 5 (1%)       | 2 (1%)           | 3 (4%)                                   |                                      |        |
| Multiple CTX schemes              | 18 (4%)      | 17 (5%)          | 11 (38%)                                 | 1 (1%)                               |        |
| Current treatment\(^5\)           | 413 (0%)     |                  |                                          |                                      |        |
| PEB                               | 395 (96%)    | 335 (98%)        | 60 (86%)                                 |                                      | 0.001  |
| PE                                | 5 (1%)       | 3 (1%)           | 2 (3%)                                   |                                      |        |
| PEI                              | 11 (3%)      | 5 (1%)           | 6 (9%)                                   |                                      |        |
| TIP                              | 1 (0%)       | 0 (0%)           | 1 (1%)                                   |                                      |        |
| VIDE                             | 1 (0%)       | 0 (0%)           | 1 (1%)                                   |                                      |        |
| Laboratory parameters (pre CTX)   |              |                  |                                          |                                      |        |
| Leukocytes (G/L)                  | 333 (19%)    | 7.0 [5.6–8.8]    | 7.4 [5.7–8.8]                            | 7.0 [5.5–8.6]                        | 0.699  |
| Neutrophiles (G/L)                | 317 (23%)    | 4.6 [3.4–6.9]    | 4.6 [3.4–6.9]                            | 4.9 [3.4–6.0]                        | 0.633  |
| Lymphocytes                      | 318          | 1.6 [1.2–2.0]    | 1.6 [1.2–2.0]                            | 1.3 [0.9–1.9]                        | 0.038  |
| Thrombocytes (G/L)                | 332 (20%)    | 254.0 [213.0–313.0] | 252.0 [213–310.0]                       | 273.0 [207.0–316.0]                     | 0.452  |
| Hemoglobin (g/dl)                 | 338 (18%)    | 15.3 [14.2–16.1] | 15.3 [14.5–16.1]                                           | 14.6 [13.1–15.6]                      | 0.001  |
| AFP                              | 348 (16%)    | 4.6 [2.5–38.0]   | 4.6.0 [2.5–35.3]                          | 4.2 [2.4–48.2]                        | 0.880  |
| ß-HCG                            | 332 (20%)    | 1.2 [1.2–14.8]   | 1.2 [1.2–14.9]                            | 1.2 [1.2–14.8]                        | 0.335  |
| LDH                              | 334 (19%)    | 192.0 [156.0–285.0]   | 188.0 [155.0–264.0]                       | 235.0 [170.0–477.0]                     | 0.005  |

Continuous data are reported as medians with 25th percentile–75th percentile in the squared brackets, and categorical data are reported as absolute frequencies and (percentages) in parentheses. Percentages are calculated by referring only to the patients without missing values (i.e., not to the total number of patients if missing values are present).

FN, febrile neutropenia; BMI, body mass index; TGCT, testicular germ cell tumor; IGCCCG, International Germ Cell Cancer Collaborative Group; AFP, alpha fetoprotein; ß-HCG, beta human choriongonadotropin; LDH, Lactate dehydrogenase.

\(^1\)p represents test for difference between FN and No FN.

\(^2\)A distinction between seminoma and nonseminoma could be made in 408 cases (in the other five cases no distinction was possible due to necrosis).

\(^3\)FN occurring during adjuvant treatment.

\(^4\)Prior treatment includes all given treatment before cisplatin-based chemotherapy; in case of several cycles of cisplatin-based chemotherapy, all cycles were counted until FN occurred; in patients without any FN episode, all cycles of cisplatin-based chemotherapy were counted.

\(^5\)Current treatment means chemotherapy regimen under which FN occurred; in patients without any FN episode, last chemotherapy regimen is cited.
Febrile Neutropenia In Testicular Cancer

A. Terbuch et al.

(19%) FN episodes occurred despite primary GCSF support. There was very little treatment delay (median: 0 days (IQR: 0–0, range: 0–7). Three patients (4%) developed a second FN episode.

Prediction of FN

In univariable logistic regression, higher age (odds ratio (OR) per 5 years = 1.17, 95% CI: 1.02–1.35, \(P = 0.022\)), reduced performance status (PS) (OR = 2.73, 1.47–5.06, \(P = 0.001\)), seminomatous histology (OR = 2.19, 1.26–3.78, \(P = 0.005\)), poor IGCCCG risk class (OR = 4.20, 1.71–10.33, \(P = 0.002\)), and prior RTX (pRTX, OR = 8.98, 2.09–38.61, \(P = 0.003\)) were associated with a higher risk of FN. In multivariable analysis adjusting for age and risk classification, only poor PS (OR = 2.06, 1.05–4.03, \(P = 0.035\)) prevailed (Table 2). In the subgroup of seminoma patients (\(n = 104\)), only pRTX predicted for FN risk (OR = 5.60, 1.24–25.34, \(P = 0.025\)). In detail, the eight seminoma patients who received pRTX had significantly lower pre-chemo white blood counts (4.7 vs. 6.5 G/L), neutrophil counts (3.2 vs. 4.3 G/L), and platelet counts (185 vs. 272 G/L) than patients without pRTX (all \(P < 0.0001\)). Five of eight seminoma patients with pRTX developed FN.

### Table 2. Predictors of FN in TGCT patients undergoing CTX – uni- and multivariable logistic regression.

| Variable | Univariable OR | 95% CI | \(P\) | Multivariable OR adjusted for age and risk classification | 95% CI | \(P\) |
|----------|----------------|--------|------|----------------------------------------------------------|--------|------|
| **Demographic characteristics** | | | | | | |
| Age (per 5 years increase) | 1.17 | 1.02–1.35 | 0.022 | N/A | N/A | N/A |
| BMI (for 5 kg/m² increase) | 0.90 | 0.65–1.25 | 0.537 | 0.83 | 0.58–1.19 | 0.302 |
| Smoker or ex-smoker | 0.62 | 0.34–1.15 | 0.133 | 0.66 | 0.35–1.23 | 0.191 |
| Karnofsky index < 100% | 2.73 | 1.47–5.06 | 0.001 | 2.06 | 1.05–4.03 | 0.035 |
| **Clinicopathological variables** | | | | | | |
| Seminomatous histology | 2.19 | 1.26–3.78 | 0.005 | 2.08 | 1.01–4.26 | 0.047 |
| T Stage | | | | | | |
| pT1 | Ref | Ref | Ref | | | |
| pT2 | 1.17 | 0.62–2.22 | 0.623 | 1.21 | 0.63–2.34 | 0.562 |
| pT3 | 2.15 | 1.06–4.37 | 0.034 | 1.83 | 0.88–3.83 | 0.106 |
| IGCCCG | | | | | | |
| Adjuvant chemotherapy (Reference) | | Ref | Ref | Ref | | |
| good risk | 1.81 | 0.95–3.45 | 0.071 | N/A | N/A | N/A |
| Intermediate risk | 2.40 | 0.93–6.21 | 0.071 | N/A | N/A | N/A |
| Poor risk | 4.20 | 1.71–10.33 | 0.002 | N/A | N/A | N/A |
| Synchronous metastasis | 1.02 | 0.44–2.35 | 0.970 | N/A | N/A | N/A |
| Primary GCSF support | 1.12 | 0.56–2.26 | 0.751 | 0.81 | 0.40–1.71 | 0.572 |
| Prior Treatment¹ | | | | | | |
| No prior treatment | Ref | Ref | Ref | | | |
| PEB chemotherapy | 6.74 | 1.76–25.83 | 0.005 | 5.50 | 1.37–22.11 | 0.016 |
| Other chemotherapy | 0.30 | 0.04–2.29 | 0.245 | 0.22 | 0.03–1.72 | 0.149 |
| Radiotherapy | 8.98 | 2.09–35.61 | 0.003 | 7.31 | 1.61–33.17 | 0.010 |
| Current chemotherapy² (PEB = reference) | | | | | | |
| Non PEB chemotherapy | 6.98 | 2.65–18.40 | <0.0001 | 4.74 | 1.72–13.08 | 0.003 |
| Laboratory parameters (pre Chemotherapy) | | | | | | |
| Leukocytes (per 1G/L increase)³ | 0.97 | 0.89–1.07 | 0.560 | 0.96 | 0.86–1.06 | 0.395 |
| Neutrophils (per 1G/L increase) | 1.03 | 0.91–1.16 | 0.613 | 1.00 | 0.88–1.14 | 0.949 |
| Lymphocytes (per 1G/L increase) | 1.07 | 0.87–1.31 | 0.550 | 1.10 | 0.89–1.37 | 0.371 |
| Thrombocytes (per 100G/L increase) | 1.04 | 0.76–1.43 | 0.801 | 0.91 | 0.65–1.26 | 0.561 |
| Hemoglobin (per 1 g/dl) | 0.78 | 0.67–0.91 | 0.001 | 0.82 | 0.69–0.97 | 0.022 |
| AFP per doubling | 1.04 | 0.95–1.12 | 0.398 | 0.99 | 0.90–1.09 | 0.887 |
| β-HCG per doubling | 1.04 | 0.98–1.10 | 0.242 | 1.01 | 0.94–1.08 | 0.848 |
| Preoperative LDH per doubling | 1.45 | 1.00–1.91 | 0.009 | 1.25 | 0.87–1.81 | 0.229 |

FN, febrile neutropenia; TGCT, testicular germ cell tumor; BMI, body mass index; N/A, not applicable; IGCCCG, International Germ Cell Cancer Collaborative Group; AFP, alpha fetoprotein; β-HCG, beta human chorionic gonadotropin; LDH, lactate dehydrogenase.

¹Prior treatment includes all given treatment before FN occurred.

²Current treatment means chemotherapy regimen under which FN occurred.

³One patient with extreme Leukocyte count excluded.
FN (63%), as compared to 22 FN cases (23%) in the 96 seminoma patients without pRTX ($P = 0.027$). We did not observe a significant correlation between white blood and platelet count and certain radiation parameters like radiation dose, radiation field size, and mean irradiated bone volume receiving at least 10 Gy (V10), 20 Gy (V20), and 25 (Gy) (data not shown).

Discussion

The present study demonstrated and confirmed that FN is a frequent complication in TGCT patients undergoing curative or adjuvant cisplatin-based chemotherapy. In detail, the FN risk in our cohort was 17%. However, treatment delay was negligible and the case fatality rate of FN in TGCT appears to be very low. Nevertheless, 80% of patients with FN had to be admitted to hospital for a median duration of 1 week, which obviously comprises quality of life during the course of chemotherapy and increases healthcare costs. With establishment of current guidelines and identification of “low-risk” patients, the admission rate nowadays might be lower. However, primary G-CSF support may have a role in reducing the burden of FN in this population. Guidelines of the major societies in the field, such as the EORTC algorithm, recommend primary G-CSF support when the predicted FN risk is above 20%. In case the FN risk is assumed to be between 10% and 20%, the decision on whether or not to prescribe primary G-CSF support should be supported by an individual assessment of FN risk factors for each patient [12]. Our data show that with a FN risk of 17%, TGCT patients fall into this “individual risk assessment” group. However, the risk factors that should be considered for this individual risk assessment according to the EORTC algorithm, such as age > 65 years poor performance status, poor nutrition status, female sex, anemia, and comorbidity, are not very prevalent in the often young and minimally comorbid TGCT population. Therefore, our study aimed to identify FN risk factors specifically for TGCT patients in order to facilitate FN risk assessment.

In detail, we could confirm a previous report by Feldman et al. that even age above 50 years is an important risk factor for FN in TGCT patients. These authors observed a 44% FN risk in TGCT patients above 50 years of age, which prompted them to recommend primary G-CSF administration for all patients in this age group [20]. Two other strong FN risk factors identified by our analysis were poor performance status and poor IGCCCG risk classification.

Moreover, seminomatous histology and prior radiotherapy emerged as risk factors for FN in the overall study cohort. Because radiotherapy is only used as adjuvant or curative treatment in SGCT and not NSGCT patients, this might explain why seminomatous histology appeared to be a risk factor for developing FN (“confounding by radiotherapy”). Clinically, a link between prior radiotherapy and a higher FN risk is highly plausible [21]. The acute depletion of bone marrow components following irradiation has been ascribed to the direct effect of radiation depleting the stem cell compartment [22]. The ability of the bone marrow compartment to recover and regenerate is dependent on the volume of bone marrow within the irradiated field. Radiotherapy to paraaortal lymph nodes involves around 25% of bone marrow [22, 23]. In our analysis, the eight seminoma patients who received pRTX had significantly lower pre-chemo white blood counts, neutrophil counts, and platelet counts than patients without pRTX (all $P < 0.0001$). The mean time from radiotherapy to relapse and subsequent chemotherapy was 1 year. This supports the hypothesis that irradiated bone marrow might not have the ability to recover or that a time interval of 1 year is too short for recovery which makes the risk of FN for relapsed seminoma patients that high.

We did not observe that the magnitude of reduction in mean blood count was associated with certain radiation parameters like radiation dose or radiation field size among seminoma patients even though there were differences in radiation dose and volume. The differences in dose and volume prescriptions are attributable to the long observation period and the change in radiation dose from 30 Gy to 20 Gy after the results from the EORTC trial 30942 in 2005 [24, 25].

Our study is limited by its retrospective character and the small sample size of the subgroup of relapsed irradiated seminoma patients. The most used regimen in our study was PEB chemotherapy (in 96% of patients) and only 4% received multiple chemotherapy regimens. Our risk stratification therefore mainly applies for TGCT patients who are treated with PEB chemotherapy as first-line treatment.

In summary, we observed a considerable risk of FN in men with TGCT undergoing cisplatin-based adjuvant or curative chemotherapy. Our study identified (1) higher age, (2) poor performance status, (3) poor IGCCCG risk classification, and (4) prior radiotherapy in the seminoma subpopulation as risk factors for FN in patients with testicular cancer.

Conflict of Interest

None of the contributing authors have any conflict of interests, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript.
References

1. Beyer, J., P. Albers, R. Altena, J. Aparicio, C. Bokemeyer, J. Busch, et al. 2013. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann. Oncol. 24:878–888.

2. Mortensen, M. S., M. Bandak, M. G. Kier, J. Lauritsen, M. Agerbæk, N. V. Holm, et al. 2017. Surveillance versus adjuvant radiotherapy for patients with high-risk stage I seminoma. Cancer 123:1212–1218.

3. Oliver, R. T., G. M. Mead, G. J. Rustin, J. k. Joffe, N. Aass, R. Coleman, et al. 2011. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J. Clin. Oncol. 29:957–962.

4. Tandstad, T., O. Stahl, U. Hakansson, O. Dahi, H. S. Hugnes, O. H. Kleep, et al. 2014. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann. Oncol. 25:2167–2172.

5. Oldenburg, J., S. D. Fossa, J. Nuver, J. K. Joffe, N. Aass, R. Coleman, et al. 2013. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl 6): vi125–vi132.

6. Gil, T., S. Sideris, F. Aoun, R. van Velt Voon, N. Sirtaine, M. Paesmans, et al. 2016. Testicular germ cell tumor: Short and long-term side effects of treatment among survivors. Mol. Clin. Oncol. 5:258–264.

7. Bezan, A., F. Posch, F. Ploner, T. Bauernhofer, M. Pichler, J. Szkandera, et al. 2017. Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. PLoS ONE 12:e0176283.

8. Feldman, D. R., G. J. Bosl, J. Sheinfeld, and R. J. Motzer. 2008. Medical treatment of advanced testicular cancer. JAMA 299:672–684.

9. Zagars, G. K., M. T. Ballo, A. K. Lee, and S. S. Strom. 2004. Mortality after cure of testicular seminoma. J. Clin. Oncol. 22:640–647.

10. Haugnes, H. S., G. J. Bosl, H. Boer, J. A. Gietema, M. Brydøy, and J. Oldenburg. 2012. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J. Clin. Oncol. 30:3752–3763.

11. Majewski, W., S. Majewski, A. Maciejewski, Z. Kolosza, and R. Tarnawski. 2005. Adverse effects after radiotherapy for early stage (I, IIa, IIb) seminoma. Radiother. Oncol. 76:257–263.

12. Aapro, M. S., J. Bohlius, D. A. Cameron, L. Dal Lago, J. P. Donnelly, and N. Kearney. 2010. update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur. J. Cancer 2011(47):8–32.

13. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. 1997. International Germ Cell Cancer Collaborative Group. J. Clin. Oncol. 15:594–603.

14. Schmoll, H. J., R. Souchon, S. Kreeke, P. Albers, J. Beyer, and C. Kollmannsberger. 2004. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann. Oncol. 15:1377–1399.

15. Cathomas, R., D. Helbling, F. Stenner, C. Rothermundt, C. Rentsch, O. Shahin, et al. 2010. Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort. Swiss Med. Wkly 140:356–369.

16. Schmoll, H. J., K. Hoffken, and K. Possinger. 1999. Kompendium Internistische Onkologie. Springer Medizin Verlag Heidelberg.

17. Rustin, G. J., G. M. Mead, S. P. Stenning, P. A. Vasey, N. Aass, and R. A. Huddart. 2007. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: medical Research Council Trial TE08, ISRCTN56475197 – the National Cancer Research Institute Testis Cancer Clinical Studies Group. J. Clin. Oncol. 25:1310–1315.

18. Klastersky, J., J. de Naurois, K. Rolston, et al. 2016. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann. Oncol. 27:v111–v118.

19. Kirkwood, B. R., and J. Sterne. 2003. Medical Statistics.

20. Feldman, D. R., M. H. Voss, E. P. Jacobsen, X. Jia, L. Graef, S. Knox, et al. 1997. Radiotherapy- associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model. Blood 89:2303–2310.

21. Dritschilo, A., and D. S. Sherman. 1981. Radiation and chemical injury in the bone marrow. Environ. Health Perspect. 39:59–64.

22. Yankelevitz, D. F., C. I. Henschke, P. H. Knapp, L. Graef, S. Knox, et al. 1997. Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model. Blood 89:2303–2310.

23. Mac Manus, M., K. Lamborn, W. Khan, A. Varghese, L. Graef, S. Knox, et al. 1997. Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model. Blood 89:2303–2310.
30 versus 20 Gy in the adjuvant treatment of stage I testicular Seminoma: a report on medical research council trial TE18, European Organisation for the research and treatment of cancer trial 30942 (ISRCTN18525328). J. Clin. Oncol. 23:1200–1208.

25. Fossa, S. D., A. Horwich, J. M. Russell, J. T. Roberts, M. H. Cullen, N. J. Hodson, et al. 1999. Optimal planning target volume for stage I testicular seminoma: a medical research council randomized trial. Medical research council testicular tumor working group. J. Clin. Oncol. 17: 1146.